Biotech Values

[DewDiligence]

IDIX update in HIV: Partner GSK has commenced a PK/food-effect study of GSK2248761 (a/k/a/ IDX899) at 100mg qD in healthy volunteers:

http://clinicaltrials.gov/ct2/show/NCT01031472

I interpret the above as good news and bad news. The bad news is that the new PK/food study will presumably delay the start of a phase-2b study by at least three months. The good news is that GSK is evidently satisfied that 100mg qD is the correct dose* and the only question is which formulation will maximize bioavailability and minimize food effects.

*Based on the completed 28-day phase-2a study that tested multiple ascending doses (http://clinicaltrials.gov/ct2/show/NCT00945282 ).